Deals Of The Week: BMS/Otsuka, Merck/Cardiome, Sanofi/Medley
Executive Summary
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.
You may also be interested in...
Sanofi Is Composing Emerging Markets Strategy: Latest Acquisition Is Brazilian Medley For $686M
Sanofi’s acquisition of Medley, Brazil’s largest generics company, reinforces its increasingly aggressive expansion in emerging markets.
Merck Pumps Pipeline With $800M Cardiome Deal
FDA-delayed vernakalant for atrial fibrillation nets handsome pact, as more-lucrative oral form awaits Phase III trials.
BMS & Otsuka Expand Their Abilify Deal, Enter into New Oncology Co-Promotion
The new deal enables BMS to smooth out its earnings in the face of a looming patent cliff and gives Otsuka an entrée into oncology.